Mannitol Viaflo Baxter

Mannitol, the active ingredient in Mannitol Viaflo Baxter, is an osmotic diuretic presented as an intravenous solution for intravenous use. It is employed to lower intracranial and intraocular pressure and to promote diuresis in renal impairment.

GNH USA supplies Mannitol Viaflo Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global healthcare facilities, offering consistent batch release and regulatory support across multiple markets.

Mannitol is used as an osmotic agent in several clinical situations where fluid shift is required.

Reduction of intracranial pressure: lowers intracranial pressure by drawing water from brain tissue into the vascular compartment. Acute glaucoma: decreases intraocular pressure rapidly to preserve vision. Renal failure diuresis: promotes urine output in patients with renal insufficiency. Drug delivery facilitation: acts as a carrier to improve the solubility and distribution of co‑administered agents.

Mannitol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal upset after infusion. - Electrolyte imbalance: especially hyponatremia or hypernatremia. - Transient hypotension: due to rapid plasma expansion.

Serious or Rare Side Effects: - Pulmonary edema: fluid overload in susceptible patients. - Acute renal failure: especially in pre‑existing kidney disease. - Hemolysis: rare but reported with high‑dose infusions.

Mannitol requires careful monitoring and specific safety measures before and during therapy.

Renal function: assess baseline renal status and monitor urine output. Electrolyte balance: check serum sodium and potassium regularly. Cardiovascular status: avoid rapid infusion in patients with heart failure or pulmonary edema. Pregnancy and lactation: use only if potential benefit justifies potential risk. Infusion rate: administer under controlled conditions to prevent sudden hemodynamic shifts. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can interact with several medicines, influencing fluid and electrolyte balance.

Major Interactions (Avoid): - Loop diuretics: may cause excessive diuresis and electrolyte loss. - Nephrotoxic agents (e.g., aminoglycosides): increase risk of renal impairment.

Moderate Interactions (Monitor Closely): - Insulin: osmotic shifts can affect glucose control. - ACE inhibitors or ARBs: may potentiate hypotensive effects. - Antihypertensive drugs: monitor blood pressure for additive lowering.